Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
SGR Repeal and Medicare Beneficiary Access Act of 2013
Client: AMERICAN MEDICAL ASSOCIATION · Firm: THE MCMANUS GROUP
Reform of the sustainable growth rate formula for Medicare physician payments. Paymet reform issues in S. 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013" & H.R. 2810 "Medicare Patient Access and Quality Improvement Act of 2013."
Employee Health Care Protection Act of 2013
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
General health care coverage and reimbursement. Food and Drug Administration legislative and regulatory issues. Tax credits for infertility treatments and H.R. 3522, The Family Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MATRIX MEDICAL NETWORK via THE MCMANUS GROUP
2014 · first_quarter · 1T
Legislation and regulation affecting health risk assessments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via THE MCMANUS GROUP
2013 · fourth_quarter · 4A
Source: Senate LDA
| 2 |
| 2013 |
| ASTELLAS PHARMA US, INC. | 2 | 2013 |
| ALLERGAN, INC. | 1 | 2013 |
| ELI LILLY AND COMPANY | 1 | 2013 |
| EMD SERONO, INC. | 1 | 2013 |
| GILEAD SCIENCES, INC. | 1 | 2013 |
Employee Health Care Protection Act of 2013
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
General health care coverage and reimbursement. Food and Drug Administration legislative and regulatory issues. Tax credits for infertility treatments and H.R. 3522, The Family Act.
SGR Repeal and Medicare Beneficiary Access Act of 2013
Client: AMERICAN MEDICAL ASSOCIATION · Firm: THE MCMANUS GROUP
Reform of the sustainable growth rate formula for Medicare physician payments. Paymet reform issues in S. 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013" & H.R. 2810 "Medicare Patient Access and Quality Improvement Act of 2013."
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: ACHAOGEN · Firm: THE MCMANUS GROUP
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Client: ACHAOGEN · Firm: THE MCMANUS GROUP
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAXOSMITHKLINE via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN MEDICAL ASSOCIATION via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Reform of the sustainable growth rate formula for Medicare physician payments. Paymet reform issues in S. 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013" & H.R. 2810 "Medicare Patient Access and Quality Improvement Act of 2013."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Medicare and Medicaid coverage, access and reimbursement issues for Hepatitis C and HIV.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATRIX MEDICAL NETWORK via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Legislation and regulation affecting health risk assessments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Opposition to Part D rebates. Medicare reimbursement issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK AND CO INC via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAXOSMITHKLINE via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN PLC via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and development environment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN INC via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
FDA approval and enforcement issues. Cosmetic safety issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACHAOGEN via THE MCMANUS GROUP
2013 · fourth_quarter · Q4
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATRIX MEDICAL NETWORK via THE MCMANUS GROUP
2013 · third_quarter · Q3
Legislation and regulation affecting health risk assessments.
Filing targets: SENATE
MERCK AND CO INC via THE MCMANUS GROUP
2013 · third_quarter · RA
General health care coverage and reimbursement; Food and Drug Administration legislative and regulatory issues; and implementation of Health Care Reform PL 111-148, Patient Protection and Affordable Care Act.
AMERICAN MEDICAL ASSOCIATION via THE MCMANUS GROUP
2013 · third_quarter · Q3
Reform of the sustainable growth rate formula for Medicare physician payments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MATRIX MEDICAL NETWORK via THE MCMANUS GROUP
2013 · third_quarter · RR
Legislation and regulation affecting health risk assessments.
EMD SERONO, INC. via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement. Food and Drug Administration legislative and regulatory issues. Tax credits for infertility treatments and H.R. 3522, The Family Act.
General health care coverage and reimbursement. Food and Drug Administration legislative and regulatory issues. Tax credits for infertility treatments and H.R. 3522, The Family Act.
ACHAOGEN via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
MERCK AND CO INC via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement; Food and Drug Administration legislative and regulatory issues; and implementation of Health Care Reform PL 111-148, Patient Protection and Affordable Care Act.
GLAXOSMITHKLINE via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement; legislative and regulatory issues related to pandemic influenza vaccine development; Implementation of Health Care Reform PL 111-148, Patient Protection and Affordable Care Act; and Food and Drug Administration legislative and regulatory issues.
ALLERGAN PLC via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement; issues related to infectious disease drug development, procurement and regulation.
ASTRAZENECA via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement; Implementation of Health Care Reform PL 111-148, Patient Protection and Affordable Care Act; Food and Drug Administration legislative and regulatory issues.
ASTELLAS PHARMA US, INC. via THE MCMANUS GROUP
2013 · third_quarter · RR
General health care coverage and reimbursement; issues related to infectious disease drug development, procurement and regulation.